DUBLIN--(BUSINESS WIRE)--The "Bacterial Conjunctivitis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Bacterial Conjunctivitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 1 and 2 respectively.
Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Bacterial Conjunctivitis - Overview
- Bacterial Conjunctivitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bacterial Conjunctivitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
Companies Mentioned
- InSite Vision Inc
- Laboratorios Sophia SA de CV
- Shire Plc
